Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacytidine + donor lymphocyte infusion
- Development stage
- Unknown
- Lead developer
- Belgian Hematology Society
- Modality
- Small Molecules, Cell Therapies
- Administration
- Intravenous
01
Overview
This combination regimen consists of the hypomethylating agent azacytidine and donor lymphocyte infusion (DLI), specifically investigated for the treatment of relapsed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) following allogeneic hematopoietic stem cell transplantation. Azacytidine, a DNA methyltransferase inhibitor, is administered sequentially before DLI to induce epigenetic modifications in leukemic cells, potentially enhancing the expression of tumor-associated antigens and sensitizing the cells to the graft-versus-leukemia (GvL) effect. The subsequent donor lymphocyte infusion provides adoptive immunotherapy by introducing donor-derived T-cells to target and eliminate residual malignant cells. This approach aims to improve clinical outcomes in patients who have failed primary transplant therapy.
- Other names
- AZA + DLISequential 5-azacytidine and donor lymphocyte infusionSequential5-azacytidine and donor lymphocyte infusionSequential-5-azacytidine and donor lymphocyte infusion
02
Targets
DNMT3B (DNA (cytosine-5)-methyltransferase 3B)DNMT3A (DNA methyltransferase 3 alpha)DNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on azacytidine + donor lymphocyte infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacytidine + donor lymphocyte infusion.